BBZA BB Biotech AG

XETRA · DE · Healthcare · Biotechnology · bbbiotech.ch

52.90EUR-1.86%Mkt Cap: 3.17B $P/E: —Today

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medica…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap3.17B USD

Enterprise Value-112.72M USD

Revenue (TTM)1.15B USD

Gross Profit1.15B USD

Net Income (TTM)628.41M USD

Revenue/Share19.24 EUR

Last Price52.90 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees10

CountryDE

SectorHealthcare

IndustryBiotechnology

ISINCH0038389992

Valuation

P/E (Trailing)—

P/E (Forward)24.82

PEG—

EV/EBITDA—

EV/Revenue-0.10

P/S2.81

P/B0.92

EPS (TTM)-8.52

EPS (Forward)2.17

52W Range

39.4063% of range60.80

52W High60.80 EUR

52W Low39.40 EUR

Profitability

Gross Margin100.00%

Oper. Margin97.74%

EBITDA Margin0.00%

Profit Margin98.49%

ROE20.81%

ROA20.75%

Growth

Revenue Growth116257.70%

Earnings Growth—

Cash Flow & Leverage

Operating CF329.11M USD

CapEx (TTM)—

FCF Margin233.15%

FCF Yield84.69%

Net Debt-3.34B USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity—

Current Ratio583.97

Quick Ratio583.91

Book Value/Sh58.68 EUR

Cash/Share55.78 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate2.25 EUR

Div. Yield—

5Y Avg Yield5.47%

Payout Ratio9.17%

Ex-Div DateMar 23, 2026

Pay Date—

Analyst Consensus

Rating—

Target (Mean)62.00 EUR

Upside (mean)+17.2%

Target Range62.00 EUR – 62.00 EUR

# Analysts1

Ownership

Shares Out.55.15M

Float—

Insiders0.08%

Institutions19.91%

Technical

SMA 5033.40 (+58.4%)

SMA 20033.40 (+58.4%)

Beta0.67

S&P 52W Chg14.58%

Avg Vol (30d)6.45K

Avg Vol (10d)0

Technical Indicators

RSI (14)37.1

MACD-0.8223

MACD Signal-0.7058

MACD Hist.-0.1165

BB Upper57.47 EUR

BB Middle55.15 EUR

BB Lower52.83 EUR

BB Width8.40%

ATR (14)0.9532 EUR

Vol Ratio (20d)0.78x